Table 2.

Medical treatment

	Control n = 12	HFpEF n = 20	HFrEF n = 20	Statistics
Beta‐blocker, n (%)	7 (58)	15 (75)	20 (100)**	vs. Control and HFpEF
ACE‐inhibitor/ARB, n (%)	9 (75)	19 (95)	19 (95)	n.s.
MRA, n (%)	0 (0)	2 (10)	16 (80)***	vs. Control and HFpEF
ARNI, n (%)	0 (0)	1 (5)	0 (0)	n.s.
Digitalis, n (%)	0 (0)	0 (0)	2 (15)	n.s.
Diuretic, n (%)	7 (58)	14 (70)	16 (80)	n.s.
Ivabradin, n (%)	0 (0)	0 (0)	1 (5)	n.s.
Nitrates, n (%)	2 (17)	0 (0)	1 (5)	n.s.
Calcium channel blocker, n (%)	4 (33)	8 (40)*	1 (5)	vs. HFrEF
Aspirin, n (%)	3 (25)	3 (15)	11 (55)*	vs. HFpEF
Oral anticoagulation, n (%)	0 (0)	10 (50)**	4 (20)	vs. Control
Statin, n (%)	5 (42)	9 (45)	12 (60)	n.s.

ACE‐inhibitor, angiotensin converting enzyme‐inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor blocker neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist.

^* P < 0.05.

^** P < 0.01.

^*** P < 0.001.